Ninepoint Partners’s Pfizer PFE Stock Holding History

Ninepoint Partners’s Portfolio PFE Stock Details PFE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-9,662	Closed	-$500K	–	92
2022 Q1	$500K	Buy	+9,662	New	+$501K	0.11%	50

Other funds holding PFE

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Ninepoint Partners's PFE Position: Q2 2022 in Review

Ninepoint Partners sold out of Pfizer (PFE) in Q2 2022, closing a stake of 9,662 shares — an estimated $500K sold.

Ninepoint Partners first reported a position in PFE in Q1 2022 and held it in 1 quarter. The position peaked at $500K in Q1 2022. 3,157 funds tracked by Wall St. Rank hold PFE as of Q2 2022.

Ninepoint Partners reported no remaining Pfizer position as of Q2 2022 after selling out during the quarter.
Ninepoint Partners sold 9,662 Pfizer shares in Q2 2022, an estimated $500K.
Ninepoint Partners first reported a position in Pfizer in Q1 2022 and held it in 1 quarter.
Ninepoint Partners's Pfizer position peaked at $500K in Q1 2022.
3,157 funds tracked by Wall St. Rank held Pfizer as of Q2 2022.

Based on Ninepoint Partners's 13F filing for Q2 2022, filed 26 Jul 2022.